Month: March 2025

Martinrea International Inc. Reports Year End and Fourth Quarter Results and Announces Dividend

Written by Customer Service on March 6, 2025. Posted in Dividend Reports And Estimates.

TORONTO, March 06, 2025 (GLOBE NEWSWIRE) — Martinrea International Inc. (TSX : MRE), a diversified and global automotive supplier engaged in the design, development and manufacturing of highly engineered, value-added Lightweight Structures and Propulsion Systems, today announced the release of its financial results for the fourth quarter and year ended December 31, 2024, and declared a quarterly cash dividend of $0.05 per share. HIGHLIGHTS Full Year 2024:Total sales of $5,014.1 million, production sales of $4,737.1 million. Adjusted EBITDA(1) of $614.8 million, 12.3% of total sales. Adjusted Operating Income Margin(1) of 5.3%. Free Cash Flow(1) (excluding principal payments of IFRS-16 lease liabilities) of $183.8 million; Free Cash Flow(1) continues to trend near record levels for the Company. Diluted net loss per share of ($0.46)...

Tarsus to Participate in Upcoming Investor Conference

Written by Customer Service on March 6, 2025. Posted in Public Companies.

IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11th, at 8:00 a.m. / 11:00 a.m. ET. A live webcast and additional information can be accessed on the events section of the Tarsus website. The replay will be available on the Tarsus website within 48 hours and will be archived for a limited time. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY®...

Globus Medical to feature ExcelsiusFlex™ for Total Knee Arthroplasty at the American Academy of Orthopedic Surgeons Annual Meeting

Written by Customer Service on March 6, 2025. Posted in Public Companies.

AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) in San Diego, Calif., from March 10-14, 2025. Join Globus at booth #2517 to learn about the comprehensive Globus Medical product portfolio across Spine, Trauma, and Joint Reconstruction procedures; Enabling Technology; Power Tools; and Regenerative Biomaterials segments. Globus will be featuring one of its latest technology innovations, the ExcelsiusFlex™ surgical robotic navigation system for Total Knee Arthroplasty (TKA), alongside its Total Joints Arthroplasty implant portfolio*. Engineered to outperform, ExcelsiusFlex™ with TKA Application consolidates accuracy, procedural...

VALHI REPORTS FOURTH QUARTER 2024 RESULTS

Written by Customer Service on March 6, 2025. Posted in Earnings Releases And Operating Results.

Dallas, Texas, March 06, 2025 (GLOBE NEWSWIRE) — Valhi, Inc. (NYSE: VHI) reported net income attributable to Valhi stockholders of $22.8 million, or $.80 per share, in the fourth quarter of 2024 compared to net income of $4.9 million, or $.17 per share, in the fourth quarter of 2023. For the full year of 2024, Valhi reported net income attributable to Valhi stockholders of $108.0 million, or $3.79 per share, compared to a net loss of $9.9 million, or $.35 per share, for the full year of 2023. Net income attributable to Valhi stockholders increased in the fourth quarter of 2024 as compared to the fourth quarter of 2023 primarily due to higher operating results from the Chemicals Segment and aggregate income of $31.4 million ($20.6 million, or $.72 per share, net of tax and noncontrolling interest) related to the settlement of a...

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on March 6, 2025. Posted in Earnings Releases And Operating Results.

Completed enrollment of 5,000 subject Phase 2b NAVIGATE trial Severe flu season enables potential mid-year assessment of efficacy Closed $105.0 million financing with new and existing investors Significantly expanded equity research coverageSAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. “2024 was a transformational year for Cidara as we reacquired rights to the CD388 program, our long-acting, universal influenza drug, and raised $240.0 million in April to conduct the 5,000 subject Phase 2b NAVIGATE trial evaluating CD388 for...

EV Realty Acquires EV Charging Platform Gage Zero’s Assets to Scale Truck Fleet Charging and Meet Long-Term Market Demand

Written by Customer Service on March 6, 2025. Posted in Mergers And Acquisitions.

This strategic consolidation of assets positions EV Realty and Gage Zero to navigate an evolving market and meet long-term fleet customer needs through an expanded regional portfolio SAN FRANCISCO, March 06, 2025 (GLOBE NEWSWIRE) — EV Realty, Inc. (“EV Realty”), an EV infrastructure development platform powering commercial fleets, today announced that it has acquired a strategic portfolio of assets from Gage Zero, an Austin-based company focused on fleet electrification and infrastructure development for local, regional, and drayage trucking fleets. Gage Zero’s approach to the market, prioritizing partnerships, industry leadership, and an equitable energy transition, generated a strategic portfolio of assets and customer relationships that complements EV Realty’s development platform strengths and growing portfolio of grid-ready,...

NL REPORTS FOURTH QUARTER 2024 RESULTS

Written by Customer Service on March 6, 2025. Posted in Earnings Releases And Operating Results.

Dallas, Texas, March 06, 2025 (GLOBE NEWSWIRE) — NL Industries, Inc. (NYSE: NL) today reported net income attributable to NL stockholders of $16.5 million, or $.34 per share, in the fourth quarter of 2024 compared to net income attributable to NL stockholders of $7.6 million, or $.16 per share, in the fourth quarter of 2023. NL’s results include an unrealized loss of $12.0 million in the fourth quarter of 2024 compared to a $2.4 million unrealized gain in the fourth quarter of 2023 related to the change in value of marketable equity securities. For the full year of 2024, NL reported net income attributable to NL stockholders of $67.2 million, or $1.38 per share, compared to a net loss attributable to NL stockholders of $2.3 million, or $.05 per share for the full year of 2023. NL’s full year results include an unrealized...

Bimini Capital Management Announces Fourth Quarter 2024 Results

Written by Customer Service on March 6, 2025. Posted in Earnings Releases And Operating Results.

VERO BEACH, Fla., March 06, 2025 (GLOBE NEWSWIRE) — Bimini Capital Management, Inc. (OTCQB: BMNM), (“Bimini Capital,” “Bimini,” or the “Company”), today announced results of operations for the three-month period ended December 31, 2024. Fourth Quarter 2024 HighlightsNet loss of $1.5 million, or $0.15 per common share Book value per share of $0.68 Company to discuss results on Friday, March 7, 2025, at 10:00 AM ETManagement Commentary Commenting on the fourth quarter results, Robert E. Cauley, Chairman and Chief Executive Officer, said, “The outlook for the fixed income market pivoted early in the fourth quarter of 2024. As the third quarter came to an end, inflation was falling towards the Fed’s 2% target, the labor market was cooling as hiring levels moderated and the unemployment rate was slowly creeping higher, and the Fed...

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Written by Customer Service on March 6, 2025. Posted in Earnings Releases And Operating Results.

– Duchenne: Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration (FDA) meeting to discuss potential accelerated approval pathways – – FA: FDA Investigational New Drug (IND) clearance for first-in-human clinical study of SGT-212 utilizing a dual route of administration to treat Friedreich’s ataxia (FA); Dosing of first participant anticipated in the second half of 2025 – – CPVT: IND for SGT-501 on track for first half 2025 submission – – Cash: Company ended 2024 with $148.9 million in cash, cash equivalents, investments and available-for-sale securities; Combined with gross proceeds from $200.0 million underwritten offering in February 2025, Solid has anticipated...

Clarus Reports Fourth Quarter and Full Year 2024 Results

Written by Customer Service on March 6, 2025. Posted in Earnings Releases And Operating Results.

Fourth Quarter Sales of $71.4 million, Adjusted EBITDA of $4.4 million, and Free Cash Flow of $14.4 million Completed the Acquisition of RockyMounts, Expanding Adventure’s Bike-Rack Product Capabilities Globally SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) — Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor enthusiast markets, reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Summary vs. Same Year‐Ago Quarter (adjusted to reflect the reclassification of the Precision Sport segment as discontinued operations)Sales of $71.4 million compared to $76.5 million. Gross margin was 33.4% compared to 28.9%; adjusted gross margin of 38.0% compared to 34.7%. Net loss, which includes the impact of discontinued operations,...

Month: March 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals